Table 1 –
Participant baseline characteristics grouped by presence or absence of PIMs, based on modified 2019 AGS Beers Criteria®
| Group | No PIM (n=11,718) |
PIM (n=7,396) |
Odds Ratio (95% CI) |
|---|---|---|---|
| Age (n and percent) | |||
| 65-69 | 393 (3%) | 173 (2%) | 0.72 (0.59,0.86) |
| 70-74 | 6,576 (56%) | 4,022 (54%) | Reference |
| 75-79 | 3,045 (26%) | 1,977 (27%) | 1.06 (0.99,1.14) |
| 80-84 | 1,098 (9%) | 840 (11%) | 1.22 (1.11,1.34) |
| 85+ | 606 (5%) | 384 (5%) | 1.04 (0.89,1.22) |
| Treatment group (n and percent) | |||
| Placebo | 5,817 (50%) | 3,708 (50%) | Ref |
| Aspirin | 5,901 (50%) | 3,688 (50%) | 1.02 (0.96,1.08) |
| Polypharmacy a | |||
| No polypharmacy | 9,885 (84%) | 4,141 (56%) | Ref |
| Polypharmacy | 1,833 (16%) | 3,255 (44%) | 4.24 (3.94,4.55) |
| Difficulty walking up one flight of stairs | |||
| No difficulty | 10,295 (88%) | 5,970 (81%) | Ref |
| Any level of difficulty | 1,423 (12%) | 1,426 (19%) | 1.72 (1.59, 1.87) |
a
Polypharmacy defined as concurrent use of 5 or more prescription medications